Diabetes Metab J.  2011 Feb;35(1):26-33. 10.4093/dmj.2011.35.1.26.

Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naive Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study

• Yoon KH
• Shin JA
• Kwon HS
• Lee SH
• Min KW
• Ahn YB
• Yoo SJ
• Ahn KJ
• Park SW
• Lee KW
• Sung YA
• Park TS
• Kim MS
• Kim YK
• Nam MS
• Kim HS
• Park IB
• Park JS
• Woo JT
• Son HY

• KMID: 2281489
• DOI: http://doi.org/10.4093/dmj.2011.35.1.26

Abstract

BACKGROUND
Although many anti-diabetic drugs have been used to control hyperglycemia for decades, the efficacy of commonly-used oral glucose-lowering agents in Korean type 2 diabetic patients has yet to be clearly demonstrated.
METHODS
We evaluated the efficacy of glimepiride, metformin, and rosiglitazone as initial treatment for drug-naive type 2 diabetes mellitus patients in a 48-week, double-blind, randomized controlled study that included 349 Korean patients. Our primary goal was to determine the change in HbA1c levels from baseline to end point. Our secondary goal was to evaluate changes in fasting plasma glucose (FPG) levels, body weight, frequency of adverse events, and the proportion of participants achieving target HbA1c levels.
RESULTS
HbA1c levels decreased from 7.8% to 6.9% in the glimepiride group (P<0.001), from 7.9% to 7.0% in the metformin group (P<0.001), and from 7.8% to 7.0% (P<0.001) in the rosiglitazone group. Glimepiride and rosiglitazone significantly increased body weight and metformin reduced body weight during the study period. Symptomatic hypoglycemia was more frequent in the glimepiride group and diarrhea was more frequent in the metformin group.
CONCLUSION
The efficacy of glimepiride, metformin, and rosiglitazone as antidiabetic monotherapies in drug-naive Korean type 2 diabetic patients was similar in the three groups, with no statistical difference. This study is the first randomized controlled trial to evaluate the efficacy of commonly-used oral hypoglycemic agents in Korean type 2 diabetic patients. An additional subgroup analysis is recommended to obtain more detailed information.

Keyword

Diabetes mellitus, type 2; Glimepiride; Metformin; Rosiglitazone

MeSH Terms

Body Weight
Diabetes Mellitus, Type 2
Diarrhea
Fasting
Glucose
Humans
Hyperglycemia
Hypoglycemia
Hypoglycemic Agents
Metformin
Plasma
Sulfonylurea Compounds
Thiazolidinediones
Glucose
Hypoglycemic Agents
Metformin
Sulfonylurea Compounds
Thiazolidinediones

Figure

• 

  Fig. 1 Enrollment and study outcomes. The total number of patients assigned to the three treatment groups was 349. A total of 36 patients left the glimepiride group, 43 left the metformin group, and 43 left the rosiglitazone group during the study period.

• 

  Fig. 2 Changes in HbA1c from baseline to end point. The black bar indicates the HbA1c level at baseline and gray bar at end point. Bars represent mean + standard deviation. aSignificant differences between HbA1c at 0 week and 48 weeks (P value<0.001). Repeated measured ANOVA test was used for statistical analysis. Between the three groups, HbA1c levels and changes were not statistically different (P value=0.62). ΔHbA1c Mean doses at end point

• 

  Fig. 3 Changes in HbA1c (A), fasting plasma glucose (FPG) (B), and body weight (C) over time, by treatment group. All panels, data are presented as mean±standard error of mean. aSignificant differences between the three treatment groups (P value<0.05).

• 

  Fig. 4 Proportion of patients achieving target HbA1c levels. Black bar indicates the proportion of patients achieving HbA1c levels less than 7.0% and white bar less than 6.5%. The χ2 test was used for comparison of differences in the three groups.

Reference

1. Kim DJ, Lee MS, Kim KW, Lee MK. Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus. Metabolism. 2001. 50:590–593.

2. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P, Son HY. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006. 368:1681–1688.

3. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009. 301:2129–2140.

4. Global risks 2009: a global risk network report. World Economics Forum. 2009. In : World Economics Forum; Geneva.

5. American Diabetes Association. Standards of medical care in diabetes--2007. Diabetes Care. 2007. 30:Suppl 1. S4–S41.

6. Riddle MC. Oral pharmacologic management of type 2 diabetes. Am Fam Physician. 1999. 60:2613–2620.

7. Bell DS. Type 2 diabetes mellitus: what is the optimal treatment regimen? Am J Med. 2004. 116:Suppl 5A. 23S–29S.

8. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006. 355:2427–2443.

9. Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabet Med. 2005. 22:980–985.

10. Task Force Team of Korean Diabetes Association. Treatment guideline for diabetes. 2007. 1st ed. Seoul: Korean Diabetes Association;48–58.

11. Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ. 2005. 172:213–226.

12. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med. 1997. 103:483–490.

13. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001. 86:280–288.

14. Tan M, Johns D, Gonzalez Galvez G, Antunez O, Fabian G, Flores-Lozano F, Zuniga Guajardo S, Garza E, Morales H, Konkoy C, Herz M. GLAD Study Group. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group trial. Clin Ther. 2004. 26:680–693.

15. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs. 1999. 58:Suppl 1. 31–39.

16. Davis SN. The role of glimepiride in the effective management of type 2 diabetes. J Diabetes Complications. 2004. 18:367–376.

17. Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther. 2004. 26:177–190.

18. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs. 2004. 64:1339–1358.

19. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995. 333:550–554.

20. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev. 2002. 18:Suppl 2. S23–S29.

21. Sohn TS, Lee JI, Kim IJ, Min KW, Son HS. The effect of rosiglitazone and metformin therapy, as an initial therapy, in patients with type 2 diabetes mellitus. Korean Diabetes J. 2008. 32:445–452.